Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

ASCO 2026

29 May - 2 Jun 2026

Published: 1 Jun 2026

Views: 32

Rating:

Save

Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada

Dr Lucy Gilbert talks to ecancer at ASCO 2026 and presents final overall survival results from the phase III ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

The addition of relacorilant to nab-paclitaxel extended overall survival in patients with platinum-resistant ovarian cancer, with a manageable safety profile and potential to reshape treatment in this difficult-to-treat setting.

Related Videos

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel...

ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )

Gene expression test guided therapy in ER+/HER2- early breast cancer allows...

Dr Robert Stein - University College London, London, UK

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )

Tarlatamab improves brain metastases control and survival compared to chemo in...

Dr Giannis Mountzios - The University of Athens, Athens, Greece

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas ( Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA )

DLL3 expression in circulating tumour cells predicts response to tarlatamab in...

Dr Avanish Mishra - Krantz Family Center for Cancer Research, Boston, USA

DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer ( Dr Avanish Mishra - Krantz Family Center for Cancer Research, Boston, USA )

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after...

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )

Cracking the code: Bispecific immunotherapy in small cell lung cancer

Prof Helena Linardou - Metropolitan Hospital, Athens, Greece

Cracking the code: Bispecific immunotherapy in small cell lung cancer ( Prof Helena Linardou - Metropolitan Hospital, Athens, Greece )

Rituximab-based chemotherapy achieves strong outcomes without routine...

Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma ( Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany )

More from ecancer